Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Jun 17, 2010

165_ip_2010-06-17_443fe92e-ccce-412f-afd6-0ef1728ca5ff.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Barclays Capital European Franchise Conference

Yountville, June 16-18, 2010

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary

We achieved record results and delivered our target

2009 Strong Revenue Growth in all Regions

Total revenue increased 6% to \$11,247 m

Impressive Growth Continued

1st Quarter 2010 – Overview

Good start into the year and on track for full-year targets Very strong underlying performance

Q
1
2
0
0
9		 Q
1
2
0
1
0		 G
t
h
r
o
w
R
e
v
e
n
u
e		 \$
2
5
6
0
m
,		 \$
2
8
8
2
m
,		 %
1
3
+
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a		 \$
1
9
8
m		 \$
2
1
1
m		 %
7
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
6
7		 \$
0
0
7		 6
%
+
  • •Superior quality performance in dialysis products as well as services
  • •Strong underlying operational performance
  • •Strong revenue growth at 10% at constant currency and 8% organic
  • •Excellent cash flow development

1st Quarter 2010 – Dialysis Services Global

Very strong revenue growth globally

\$
U
S
i
l
l
i
m
o
n
s		 Q
1
2
0
0
9		 Q
1
2
0
1
0		 G
t
h
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 1
5
7
7
,		 1
6
0
7
,		 1
2
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 3
4
6		 4
1
1		 1
9
%		 9
%
T
l
t
o
a		 1
9
2
3
,		 2
1
1
7
,		 1
3
%		 1
1
%
  • •Good organic treatment growth
  • •Continued strong revenue-per-treatment development
  • •Treating 198,774 patients in ~ 2,580 clinics

cc = constant currency

1st Quarter 2010 – Quality Outcomes

Overall strong quality performance

N
t
h
A
o
r
m		 (
S
i
U
A
e
r
c
a		 E
)		 M
E
A
%
f
i
t
t
o
p
a
e
n
s		 Q
1
2
0
0
9		 Q
1
2
0
1
0		 Q
1
2
0
0
9		 Q
1
2
0
1
0
/
K
t
V
1
2
≥		 %
9
6		 %
9
6		 %
9
4		 %
9
5
H
l
b
i
1
0
1
2
/
d
l
e
m
o
g
o
n
g
=
-		 6
2
%		 6
5
%		 5
1
%		 5
2
%
A
l
b
i
3
/
d
l
5
≥
u
m
n
g		 8
0
%		 8
3
%		 8
4
%		 8
%
5		 I
m
p
r
o
v
e
/
P
h
h
t
3
5
5
5
d
l
o
s
p
a
e
m
g
-		 %
5
3		 %
5
5		 %
6
1		 %
6
1		 I
m
p
r
o
v
e
H
i
l
i
i
d
t
t
o
s
p
a
z
a
o
n
a
y
s		 1
0
4		 *
9
9		 8
2		 8
9

The hospitalization rates for the US reflects adoption of CMS policy *

1st Quarter 2010 – Quality Outcomes

Focus on quality & innovation for our patients

%
f
i
Q
1
2
0
1
0
t
t
o
p
a
e
n
s		 S
U
A		 C
l
i
i
n
c
N
l
t
o
c
u
r
n
a		 E
M
E
A		 O
l
i
n
n
e
H
D
F
/
K
t
V
≥
1
2		 %
9
6		 %
9
9		 9
%
5		 %
9
7
/
A
l
b
i
≥
3
5
d
l
u
m
n
g		 %
8
3		 %
9
3		 8
%
5		 %
8
7
/
P
h
h
t
3
5
5
5
d
l
o
s
p
a
e
g
-		 %
5
5		 %
5
6		 %
6
1		 %
6
1

1st Quarter 2010 – Revenue per treatment US

Favorable reimbursement environment

Rationale for ESRD Integrated Care Model

CMS annual costs per ESRD patient – \$87,400

1st Quarter 2010 – Dialysis Products

Product growth with sequential improvement

\$
S
U
i
l
l
i
m
o
n
s		 Q
1
2
0
0
9		 Q
1
2
0
1
0		 G
t
h
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
inc
l.
in
l re
)
ter
na
ve
nu
e		 8
8
5		 9
6
9		 1
3
%		 %
7
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 6
3
7		 1
1
7		 1
2
%		 %
5
N
t
h
A
i
o
r
m
e
r
c
a		 1
9
7		 2
0
0		 %
1
I
i
l
t
t
n
e
r
n
a
o
n
a		 4
4
0		 1
1
5		 1
6
%		 %
7

cc = constant currency

Excellent cash flow performance

\$
S
U
i
l
l
i
m
o
n
s		 Q
1
2
0
0
9		 Q
1
2
0
1
0		 G
h
t
r
o
w
1)
O
i
h
f
l
t
p
e
r
a
n
g
c
a
s
o
w		 1
5
6		 3
4
9
1
2
%
f r
o
ev
en
ue		 %
1
2
4
1)
C
i
l
d
i
t
t
t
a
p
a
e
x
p
e
n
u
r
e
s
n
e
,		 (
1
1
1
)		 (
9
9
)
F
h
f
l
r
e
e
c
a
s
o
w		 4
5		 2
0
5
9
%
f r
o
ev
en
ue		 %
4
5
7
1)
A
i
i
t
i
f
t
d
i
t
i
t
c
q
u
s
o
n
s
n
e
o
e
s
r
e
s
v
u
,		 (
3
6
)		 (
)
8
2
1)
F
h
f
l
f
i
i
i
r
e
e
c
a
s
o
t
t
w
a
e
r
a
c
q
u
s
o
n
s
,		 9 1
6
8
6
%
f r
o
ev
en
ue

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

1st Quarter 2010 – Debt and EBITDA Development

Debt/EBITDA ratio ahead of target

* including non-cash charges and in 2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

1st Quarter 2010 –Summary

Superior quality performance in both products and services

Continued expansion of new products and therapies worldwide

Strong underlying operational performance

Excellent cash flow development

Continued focus on R&D

Reiterated full-year guidance 2010

Fiscal Year 2010 – Outlook

\$ in millions

R 1
e 2
e 0
n 0
e 0
v >
u ,
N
t
i
e
n
c
o
m
e		 \$
9
0
9
8
0
5
-
C
i
t
l
d
i
t
a
p
a
e
x
p
e
n
u
r
e
s		 \$
5
5
0
6
8
0
-
--------------------------------------------------------------------------------------------- ---------------------------------------

Strong growth expected for 2010

Agenda

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary

Global Presence Products & Services

Dialysis Services Worldwide – Number of Patients Treated 2009*

* Based on company statements and estimates

* * 13,606 patients including managed clinics

Market Position Globally

1,895,000 Dialysis Patients in 2009

Dialysis patients treated in 2009 by company

Market Position by Major Product Groups

R
k
1
a
n		 R
k
2
a
n		 R
k
3
a
n
D
i
l
a
y
z
e
r
s		 F
M
E		 G
b
a
m
r
o		 N
i
p
r
o
D
i
l
i
h
i
a
s
s
m
a
c
n
e
s
y		 F
M
E		 G
b
a
m
r
o		 N
i
k
k
i
s
o
H
d
i
l
i
t
t
e
m
o
a
y
s
s
c
o
n
c
e
n
r
a
e
s		 F
M
E		 F
u
s
o		 G
b
a
m
r
o
B
l
d
l
i
o
o
n
e
s		 F
M
E		 G
b
a
m
r
o		 K
i
a
w
a
s
u
m
P
i
l
d
i
l
i
d
t
t
e
r
o
n
e
a
a
s
s
p
r
o
c
s
y
u		 B
t
a
e
r
x		 F
M
E		 P
i
s
a

Produced more than ~85,000,000 Dialyzers in 2009

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary

Global View of Dialysis Patients

Global prevalence increased by 80% over the last 10 years

ESRD patients per million population (p.m.p.)

Dedication to Quality

Services – Reduction in Mortality

North America 2005 – 2009: 21%

Europe 2005 – 2009: 13%

Products – Bloodlines

Reynosa, Mexico 2002 – 2010: 85% Improvement in Quality

Achieved less than 3 complaints per million while producing 73 million bloodlines per year

Development of Dialysis Patient Numbers

  • Renal failure persists worldwide
  • Dialysis is the primary treatment modality on a global scale
  • The number of global dialysis patients is expected to double by 2020

Continued Growth Opportunities

Our global presence, growth and profitability is market leading

Vertical integration was and will be the best business model

There are many opportunities but also challenges

We will confidently continue to pursue our growth strategy, and we will remain vigilant with respect to:

Thank You for your interest in Fresenius Medical Care !

Barclays Capital, June 16-18, 2010 © 2010 Fresenius Medical Care AG & Co. KGaA

Forward-looking Statements

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Fresenius Medical Care

The World's Leading Renal Therapy Company

Barclays Capital European Franchise Conference

Yountville, June 16-18, 2010

Attachment I

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

D
b
t
e		 Q
1
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7
S
(
/
)
ho
t-
te
bo
ing
inc
l.
A
R
r
rm
rro
w
s
p
ro
g
ra
m		 9
9		 3
1
6		 6
8
4		 2
1
7
S
ho
t-
ter
bo
ing
fro
la
te
d p
t
ies
+
r
m
rro
s
m
re
ar
w		 1
0		 1
0		 1 2
Cu
f
t p
t
ion
lon
ter
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
+
rre
n
or
o
g-
m
n
ap
se
o
a
s		 1,
5
4
4		 1
5
8		 4
5
5		 8
5
Cu
t p
t
ion
f
tru
t p
fer
d s
i
t
ies
+
rre
n
or
o
s
re
re
ec
ur		 6
7
0
Lo
de
b
d c
i
l
lea
b
l
ig
ion
-te
t a
ta
t
+
ng
rm
n
ap
se
o
a
s,
les
t p
t
ion
s c
urr
en
or		 3,
0
2
9		 4,
4
2
8		 3,
9
7
5		 4,
0
0
4
Tr
t p
fer
d s
i
t
ies
les
t p
t
ion
+
us
re
re
ec
ur
s c
urr
en
or		 6
2
8		 6
5
6		 6
4
1		 6
6
4
To
ta
l
de
b
t
=		 5,
3
1
0		 5,
5
6
8		 5,
7
3
8		 5,
6
4
2
E
B
I
T
D
A		 Q
1
2
0
1
0		 F
Y
2
0
0
9		 1)
F
Y
2
0
0
8		 F
Y
2
0
0
7
La
t
tw
lve
t
hs
t
ing
inc
(
E
B
I
T
)
s
e
m
on
o
p
er
a
om
e		 1,
7
8
3		 1,
7
5
6		 1,
6
7
2		 1,
5
8
0
La
t
tw
lve
t
hs
de
ia
t
ion
d a
t
iza
t
ion
+
s
e
m
on
p
rec
an
mo
r		 4
6
7		 4
5
7		 4
1
6		 3
6
3
No
h c
ha
+
n-c
as
rg
es		 5
1		 5
0		 4
4		 4
1
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 2,
3
1
0		 2,
2
6
3		 2,
1
3
2		 1,
9
8
4

1) Excluding restructuring costs and in-process R&D

Attachment II

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

E
t
l
R
e
r
n
a
e
e
n
e
x
v
u
C
i
t
l
d
i
t
(
t
)
a
p
a
e
x
p
e
n
u
r
e
n
e		 Q
1
2
0
1
0		 Q
1
2
0
0
9
Pu
ha
f p
ty,
lan
t a
d e
ip
t
rc
se
o
ro
p
er
p
n
q
u
me
n		 (
1
0
6
)		 (
1
1
2
)
Pr
ds
fro
le
f p
ty,
lan
t a
d e
ip
t
oc
ee
m
sa
o
ro
p
er
p
n
q
u
me
n
-		 7 1
Ca
(
)
i
ta
l e
d
i
tu
t
=
p
xp
en
re
ne		 (
)
9
9		 (
)
1
1
1
A
i
i
t
i
(
t
)
c
q
u
s
o
n
s
n
e		 Q
1
2
0
1
0		 Q
1
2
0
0
9
Ac
is
i
ion
d
inv
d
ha
f
in
i
b
le
t
tm
t a
t p
ta
ts
q
s a
n
es
en
n
ne
ur
c
se
s o
ng
as
se
u		 (
8
4
)		 (
3
)
7
Pr
ds
fro
d
ive
i
t
tu
oc
ee
m
s
re
s		 2 1
Ac
is
i
t
io
t o
f
d
ive
t
i
tu
q
u
ns
ne
s
re
s
,		 (
8
2
)		 (
3
6
)

All figures are in \$ millions

cc = constant currency

Dialysis Services - Global

Q
1
2
0
1
0		 C
l
i
i
n
c
s		 P
t
i
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
ion
)
m
s
T
t
l
o
a		 2
8
0
5
,		 1
9
8
7
7
4
,		 7
5
G
h
t
r
o
w		 %
5
+		 6
%
+		 %
7
+
N
t
h
A
i
o
r
m
e
r
c
a		 1
7
8
8
,		 1
3
3
1
0
5
,		 5
0
G
t
h
r
o
w		 %
4
+		 %
5
+		 %
6
+
I
t
t
i
l
n
e
r
n
a
o
n
a		 9
2
7		 6
6
6
9
5
,		 2
5
G
h
t
r
o
w		 8
%
+		 9
%
+		 8
%
+
E
u
r
o
p
e		 4
5
5		 3
2
2
4
7
,		 1.
3
L
t
i
A
i
a
n
m
e
r
c
a		 1
9
2		 2
1,
3
1
7		 0
8
A
i
P
i
f
i
s
a-
a
c
c		 1
4
5		 1
0,
1
2
5		 0
4

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse-Kröner-Str. 161352 Bad Homburg v.d.H.

Oliver MaierHead of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 E-mail: [email protected]

Gerrit Jost

Tel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 E-mail: [email protected]

Terry L. Morris Tel.: +1-800-948-2538Fax.: +1-615-345-5605E-mail: [email protected] Ordinary shares WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

Reminder …

Q
2
2
0
1
0
R
l
t
e
s
s
u		 – C
f
C
l
l,
A
t
3,
2
0
1
0
o
n
e
r
e
n
c
e
a
g
s
u
u
C
i
l
M
k
D
t
t
a
p
a
a
r
e
a
y		 – S
b
1-
2,
2
0
1
0,
L
d
U
K
t
e
p
e
m
e
r
o
n
o
n,
Q
3
2
0
1
0
R
l
t
e
s
u
s		 – C
f
C
l
l,
N
b
2,
2
0
1
0
o
n
e
r
e
n
c
e
a
o
v
e
m
e
r

For recent updates, please have a look at our website. www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our Shares

Fresenius Medical Care

The World's Leading Renal Therapy Company

Barclays Capital European Franchise Conference

Yountville, June 16-18, 2010

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.